Downregulation of lncRNA ZFAS1 inhibits the hallmarks of thyroid carcinoma via the regulation of miR-302-3p on cyclin D1

WENJING CHEN¹, LILI ZHAI¹, HUIMING LIU¹, YUTING LI¹, QI ZHANG¹, DANDAN XU¹ and WEIYE FAN²

Departments of ¹Pathology and ²Thyroid Surgery, The First Hospital of Qiqihar, Affiliated Qiqihar Hospital, Southern Medical University, Qiqihar, Heilongjiang 161000, P.R. China

Received November 13, 2019; Accepted July 23, 2020

DOI: 10.3892/mmr.2020.11640

Abstract. At present, treatment options for thyroid carcinoma remain limited. The present study aimed to investigate the role of ZFAS1 in various major hallmarks of cancer and the underlying mechanisms in thyroid carcinoma cells. The interactions between long non-coding RNAs (lncRNAs), microRNAs (miRs) and target genes were predicted by bioinformatics and confirmed by performing dual-luciferase assays. The mRNA and protein expressions were determined by reverse transcription-quantitative PCR and western blotting. Cell invasion, migration, and viability were evaluated via Transwell, wound-healing and Cell Counting Kit-8 assays, respectively.

The results demonstrated that IncRNA ZFAS1 expression was upregulated in thyroid carcinoma tissues, TT and SW579 cells, and was associated with the proliferation of these two cell lines. Notably, downregulation ZFAS1 reduced migration and invasion, and reversed the promotive effects of miR-302a-3p inhibitor on the proliferation, migration and invasion of TT and SW579 cells. Moreover, cyclin D1 (CCND1) is targeted by miR-302a-3p, and was regulated by ZFAS1. In addition, the downregulation of ZFAS1 not only reversed the promotive effects of miR-302a-3p inhibitor on CCND1 expression and the epithelial-mesenchymal transition (EMT) of TT and SW579 cells, but also targeted and increased the expression of miR-302a-3p, and further reduced the expression of CCND1, resulting in suppression of the proliferation, migration, invasion and EMT of thyroid carcinoma cells.

Introduction

Thyroid carcinoma, which is a common malignant tumor of the endocrine system (1), has one of the highest incidence rates for malignant tumors in a number of regions (1,2), such as the United States (3), Korea (4) and southern European countries (5). According to the latest data from the American Cancer Society, there were 52,070 new cases and 2,170 mortalities of thyroid carcinoma in 2019 (3). According to its pathological characteristics, thyroid cancer can be divided into papillary thyroid cancer, follicular thyroid cancer, medullary thyroid carcinoma and undifferentiated thyroid carcinoma (6). At present, the treatments for differentiated thyroid cancer are mainly surgical resection, thyroid-stimulating hormone inhibition treatment, radioactive iodine treatment and molecular-targeted therapy (7). However, due to the strong invasive and migratory nature of thyroid cancer and its high degree of malignancy, recurrence or distant metastasis often occurs in a number of patients after treatment (8). Thus, investigation of the molecular mechanisms involved in the metastasis of thyroid carcinoma, and development of molecular markers and targets of thyroid carcinoma are important for the treatment of the cancer.

Long non-coding (Inc)RNAs are RNAs with >200 nucleotides in length and without protein-coding functions (9). IncRNAs have been reported to regulate numerous biological processes (9); for example, IncRNAs participate in the growth and development of the human body and occurrence of numerous diseases (9), such as cancer (10) and glomerular and tubulointerstitial kidney disease (11). A previous study indicated that the genome is widely transcribed and regulated by IncRNAs, and various IncRNAs serve important roles in different biological processes, such as in chromatin remodeling, transcription, cleavage and translation (12). Gene expression profiling of tumors is indicative of abnormal expressions of IncRNAs in tumors, and functional studies have reported that IncRNAs are involved in general mechanisms underlying tumorigenesis (13,14).

ZFAS1 serves a role in atherosclerosis (15) and a variety of cancer types (16-19), such as ovarian cancer, breast cancer, prostate cancer and hepatocellular carcinoma. ZFAS1 is a candidate biomarker predictive of the prognosis of thyroid carcinoma (20). Han et al (20) reported that Homo sapiens (hsa)-microRNA (miRNA/miR)-150-5p and hsa-miR-590-3p are competitive endogenous RNAs related to ZFAS1 in thyroid cancer cells. ZFAS1 promotes progression of papillary thyroid carcinoma by sponging miR-590-3p and increasing high-mobility group AT-hook 2 expression (21). IncRNAs...
sponge different miRNAs to regulate the cellular functions (22). Additionally, it has been reported that miR-302a-3p serves a role in a variety of diseases, such as hepatocellular carcinoma (23) and pancreatic ductal adenocarcinoma (24). Long intergenic non-protein coding RNA (LINC)01016 promotes the malignant phenotype of endometrial cancer cells by regulating the miR-302a-3p/miR-3130-3p/nuclear transcription factor Y subunit α/SATB homeobox 1 axis (25). In addition, miR-302a-3p suppresses the progression of hepatocellular carcinoma by inhibiting proliferation and invasion of the tumor cells (23). However, the role of miR-302a-3p in thyroid carcinoma has not been reported.

The present study investigated the role of ZFAS1 in the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of thyroid carcinoma cells, and explored the downstream miRNA and target gene via which ZFAS1 exerted its regulatory effects on thyroid carcinoma cells.

Materials and methods

Patients. This study was approved by the Ethics Board of The First Hospital of Qiqihar (approval no. QR20180503112). Samples (n=30) from carcinoma as well as the adjacent tissue (≤5 cm away from the cancer tissue) were extracted from patients (age range, 28-65 years; mean age, 41.2±8.24 years; males, 11; females, 19) diagnosed with thyroid carcinoma in the First Hospital of Qiqihar between June 2018 and April 2019. The inclusion criteria of patients in this study were as follows: Patients who were identified as thyroid carcinoma via pathological examination; and patients who did not receive radiotherapy or chemotherapy before the surgery. Written informed consent was obtained from patients in this study. Based on the median expression value of ZFAS1, the patients were separated into low and high expression groups.

Cell culture. Nthy-ori3-1 (Shanghai YaJi Biological Technology Co., Ltd.; http://www.yajimall.com/) (26), MDA-T68 [American Type Culture Collection (ATCC)] (27), SW579 (ATCC) (28), B-CPAP (The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences) (29) and TPC-1 (The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences) (30) cell lines were cultured in RPMI 1640 (cat. no. 21875091; Thermo Fisher Scientific, Inc.). The TT and SW579 cells (1x10^5 cells/well) were transfected using Lipofectamine 3000 (cat. no. L3000015; Thermo Fisher Scientific, Inc.). The cells were cultured for 24 h prior to subsequent experimentation.

Reverse transcription-quantitative (RT-q)PCR. The total RNAs were extracted from the tissue samples and cells (1x10^5 cells) using TRIzol® reagent (cat. no. 15596018; Thermo Fisher Scientific, Inc.). For mRNA analysis, cDNA synthesis was performed on 200 ng of total RNA using a TaqMan™ MicroRNA Reverse Transcription Kit (cat. no. 4366597; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Reverse transcription conditions included: 42˚C for 30 min and at 85˚C for 5 min. The qPCR reactions was performed using 2 µl cDNA solution, 5 µl TaqMan 2X Perfect Master Mix (Takara Biotechnology Co., Ltd.), 0.25 µl gene-specific primers and 2.75 µl of nuclease-free water in a total volume of 10 µl with a Bio-Rad IQ5 thermocycler (Bio-Rad Laboratories, Inc.) under the following conditions: Initial denaturation at 95˚C for 3 min, followed by 40 cycles at 95˚C for 30 sec, 62˚C for 30 sec and 72˚C for 25 sec. The U6 gene was used as an internal control. For miRNA analysis, the mRNA templates were reverse transcribed into cDNAs using PrimeScript RT reagent kit (Takara Biotechnology Co., Ltd.). Reverse transcription conditions: At 37˚C for 30 min and at 85˚C for 5 min. According to the protocol of FastStart™ Universal SYBR-Green Master (Rox; cat. no. 491385001; Roche Diagnostics), 14 µl 2X SYBR-Green master mix, 1 µl forward primer (10 µM), 1 µl reverse primer (10 µM), 3 µl cDNA template and 6 µl double distilled H2O were mixed and reacted in a Bio-Rad IQ5 thermocycler (Bio-Rad Laboratories, Inc.) under the following conditions: 95˚C for 90 sec, 95˚C for 25 sec, 65˚C for 20 sec, 72˚C for 30 sec for 40 cycles. GAPDH was used as an internal control. mRNA expression levels were calculated by the 2^(-ΔΔCq) method (31). The primers used for RT-qPCR were shown in Table I.

Transwell assay. The TT and SW579 cells (1x10^5) were collected at the logarithmic growth phase, and pipetted into the upper chamber (containing serum-free medium) of a Transwell insert (8-µm) pre-coated with Matrigel (BD Bioscience; at 37˚C for 4 h). The lower chamber was supplemented with 10% FBS mixed in 400 µl medium. Transwell was incubated at 37˚C with 5% CO2 for 24 h. Next, cells remaining on the surface of the upper chamber were removed with a cotton swab, the invading cells were fixed with 4% paraformaldehyde for 15 min at room temperature and then stained with 0.2% crystal violet for 10 min at room temperature. The cells in the lower chamber were observed under a light microscope (magnification, x200), and the cells were counted using Image J software (version 1.8.0; National Institutes of Health).
Bioinformatics and dual-luciferase reporter assay. The interactions between ZFAS1 and miR-302a-3p, and cyclin D1 (CCND1) and miR-302a-3p were predicted by Starbase (version 2.0; http://starbase.sysu.edu.cn). The mutants of ZFAS1 and CCND1 were built using a Quick-Change Site-Directed Mutagenesis kit (Agilent Technologies, Inc.). pGL3 plasmid encoding a luciferase reporter gene was purchased from Promega Corporation. Recombinant plasmids containing the wild-type (WT) ZFAS1-3'-untranslated region (UTR), WT CCND1-3' UTR or corresponding mutant sequences were constructed. The TT and SW579 cells (1x10^5 cells/well) were transfected with miR-302a-3p mimic (40 nM; 5'-UAA GUG CUU CCA UGU UUU GGU GA-3'; Shanghai GenePharma Co., Ltd.) or miRNA control (40 nM; 5'-UUC UCC GAA CGU GUC ACG UTT-3'; Shanghai GenePharma Co., Ltd.), recombinant plasmid (20 ng) or corresponding mutants (20 ng) using Lipofectamine 3000. Plasmid pRL-Thymine kinase (TK; Promega Corporation) was used as an internal reference luciferase. The cells were cultured for 48 h prior to the detection of luciferase activity using a Dual-Glo luciferase assay kit (Promega Corporation). The firefly luciferase activity was normalized to Renilla luciferase activity.

Wound healing assay. TT and SW579 cells (1x10^6) were collected at the logarithmic growth phase. A gap in the middle of the cell layer was created using a sterile 200-µl pipette tip by scratching the monolayer of cells. After washing, the cells were treated with serum-free medium for 48 h and incubated with 5% CO_2 at 37°C. The images were captured using a light microscope (magnification, x100) and analyzed via ImageJ software 1.8.0 (National Institutes of Health). The mean distance between the upper, middle and bottom edges of the gap were measured and recorded.

Cell Counting Kit-8 (CCK-8) assay. The TT and SW579 cells (1x10^6) were transfected with si-ZFAS1 or miR-302a-3p inhibitor, divided into groups (control, si-control, si-ZFAS1, inhibitor-NC, inhibitor, inhibitor + si-ZFAS1) and cultured for 24, 48 and 72 h. The cell viability was detected by a CCK-8 assay (cat. no. 96992-100TESTS-F; Sigma-Aldrich; Merck KGaA) according to the manufacturer's protocol. The absorbance was determined at 450 nm using a Multiskan microplate reader (Thermo Fisher Scientific, Inc.).

Western blotting. Following cell transfection for 24 h, 1x10^6 cells were obtained and lysed using RIPA lysate (cat. no. R0278; Sigma-Aldrich; Merck KGaA) with protease inhibitor (cat. no. S8830; Sigma-Aldrich; Merck KGaA) to extract the total protein. The bicinchoninic acid method (cat. no. BCA1; Sigma-Aldrich; Merck KGaA) was used to determine the concentration of total protein. The proteins (25 µg/lane) were separated by 12% SDS-PAGE, and then transferred to a PVDF membrane. The membrane was blocked with 5% non-fat milk for 1 h at room temperature and incubated with anti-cyclin D1 (1:10,000; cat. no. ab134175; 34 kDa), matrix metalloproteinase (MMP)-9 (1 µg/ml; cat. no. ab73734; 72 kDa), MMP2 (1:1,000; cat. no. ab37150; 72 kDa), E-cadherin (1:10,000; cat. no. ab40772; 97 kDa), N-cadherin (1 µg/ml; cat. no. ab18203; 130 kDa); and GAPDH (1:10,000; cat. no. ab181602; all purchased from Abcam) primary antibodies overnight at 4°C. The membrane was then washed with TBS-Tween 20 (0.1% Tween-20) and incubated with horseradish peroxide-conjugated goat anti-rabbit secondary antibody (1:2,000; cat. no. ab205718; Abcam) for 1 h at room temperature. The proteins blots were developed using SignalFire™ ECL Reagent (cat. no. 6883; Cell Signaling Technology, Inc.) and quantified using ImageJ Software (version 1.46; National Institutes of Health).

| Gene       | Primer sequence (5’→3’)               |
|------------|---------------------------------------|
| LncRNA ZFAS1 | F: CTATTGTCTTCCGGCTGTAGAGTATTGTCCTGCCCGTTAGAG  |
|            | R: GTCAAGGAGATCGAGGAAGTTGTAG          |
| miR-302a-3p | AATAAGTGCTTCCATGTTTGGTA               |
| Cyclin D1  | F: GTCTTTCCGCTGGGCACTAACTAC           |
|            | R: GGAAGGCTTGAGACCGGTAGTGGTA          |
| MMP2       | F: GGAGGCACGATTGTGCTG                 |
|            | R: TTGGTTTCCCGCATTGTCTG               |
| MMP9       | F: TGTAAGGGGTATGGTGAC                 |
|            | R: CCTCAAGGTTTGGGAAT                  |
| E-cadherin | F: TAACCGATAGAAAATG                  |
|            | R: TTTGTAGAGGCAGCTAGGAT               |
| N-cadherin | F: AGTGAAGGCTAAGTAAAAAGATTGGATG      |
|            | R: CACCTGACACTTTTCTGGGCTCTT           |
| GAPDH      | F: CGCTTACGGAATTTTGCCTGTCA           |
|            | R: GAAGATGTTAGAGGGATTTTC             |
| U6         | F: TGCCGGGTGCTCCTGGCCAG            |
|            | R: CCAGTGCGAGGGTCCCAGCT             |

lncRNA, long non-coding RNA; miR, microRNA; MMP, matrix metalloproteinase; F, forward; R, reverse.
Statistical analysis. Data were expressed as the mean ± SD of three independent experiments. The statistical differences between two groups were analyzed by paired and unpaired Student’s t-test, whereas differences among multiple groups were analyzed by one- or two-way analysis of variance followed by Tukey’s post hoc test. Pearson’s correlation coefficient test was used for the analysis of correlation, Fisher’s exact test and χ² test used to analyze associations between categorical variables. All results were analyzed using GraphPad Prism 8.0 (GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

ZFAS1 expression levels in tissues and cell lines of thyroid carcinoma are upregulated and positively associated with the proliferation of thyroid carcinoma cells. In order to determine the expression and effects of ZFAS1 in thyroid carcinoma, the expression levels of ZFAS1 in tumor tissues and cell lines were detected. In addition, the cell viabilities of TT and SW579 cells with silencing ZFAS1 were determined. The results demonstrated that ZFAS1 expression levels were upregulated in thyroid carcinoma tissues compared with in adjacent tissues, and were upregulated in MDA-T68, TT, SW579, B-CPAP and TPC-1 cells compared with in Nthy-ori3-1 cells (P<0.01; Fig. 1A and B). In addition, the associations between ZFAS1 expression and clinical characteristics were analyzed, and the results demonstrated that ZFAS1 expression levels were significantly associated with tumor size, lymph node status and tumor stage (Table II). In addition, ZFAS1 expression levels were significantly decreased in the si-ZFAS1 group compared with those of the si-control group in TT and SW579 cells (P<0.01; Fig. 1C and D). Notably, the cell viabilities of TT and SW579 cells were significantly lower in the si-ZFAS1 group compared with those of the si-Control group after 24, 48 and 72 h (P<0.05 or P<0.01; Fig. 1E and F). These results suggested that the expression levels of ZFAS1 were elevated in thyroid carcinoma and associated with the proliferation of thyroid carcinoma.
Reduction of ZFAS1 expression levels reduces the migratory and invasive ability of thyroid carcinoma cells. TT and SW579 cells were transfected with si-ZFAS1 to further observe the effects of ZFAS1 on the migratory and invasive ability of thyroid carcinoma cells. The results demonstrated that the migration and invasion rates of TT and SW579 cells were significantly decreased in the si-ZFAS1 group compared with the si-Control group after 24 h (P<0.01; Fig. 2), suggesting that ZFAS1 expression was positively associated with the migratory and invasive ability of thyroid carcinoma cells.

miR-302a-3p is targeted by ZFAS1. Bioinformatics predicted that miR-302a-3p was the target gene of ZFAS1 (Fig. 3A); thus, the relationship between miR-302a-3p and ZFAS1 was further examined. The results demonstrated that the relative luciferase activity was significantly decreased in the ZFAS1-WT + mimic group in TT and SW579 cells compared with those of the ZFAS1-WT + blank groups (P<0.01; Fig. 3B and C), which indicated that miR-302a-3p was a target of ZFAS1. In addition, the results demonstrated that miR-302a-3p expression levels were significantly decreased in thyroid carcinoma tissues compared with those of adjacent tissues (P<0.01; Fig. 3D), and that there was a negative relationship between the expression levels of ZFAS1 and miR-302a-3p (Fig. 3E). In addition, the expression levels of miR-302a-3p in the inhibitor group were significantly decreased compared with those of the inhibitor-NC group, but were significantly higher in the inhibitor + si-ZFAS1 group compared with those of the inhibitor group in TT and SW579 cells (P<0.01; Fig. 3F and G). In addition, the miR-302a-3p expression levels in the si-ZFAS1 group were significantly increased compared with those in the inhibitor + si-ZFAS1 group (P<0.01; Fig. 3F and G). Taken together, these results suggested that ZFAS1 may target miR-302a-3p to regulate the activity of thyroid carcinoma cells.

Downregulation of ZFAS1 expression levels eliminates the positive effects of miR-302a-3p inhibition on the proliferation, migration and invasion of thyroid carcinoma cells. To investigate the roles of ZFAS1 and miR-302a-3p in the progression of thyroid carcinoma, the changes of the cell viability, migration and invasion in thyroid carcinoma cells treated with or without si-ZFAS1 and miR-302a-3p inhibitor were examined. The results demonstrated that the cell viability, and migration and invasion rates in the inhibitor group of TT and SW579 cells were significantly increased compared with those of the inhibitor-NC group, but they were significantly decreased in the inhibitor + si-ZFAS1 group compared with those of the inhibitor group (P<0.01; Fig. 4). In addition, the cell viability, and migration and invasion rates were significantly decreased in the si-ZFAS1 group compared with the inhibitor + si-ZFAS1 group (P<0.01; Fig. 4). These results suggested that downregulation of ZFAS1 may attenuate the reduced expression of miR-302a-3p in thyroid carcinoma.

miR-302a-3p targets CCND1. The gene via which ZFAS1 and miR-302a-3p exerted their regulatory roles in thyroid carcinoma was determined via bioinformatic analysis. Bioinformatic analysis predicted that CCND1 is targeted by miR-302a-3p in the development of thyroid carcinoma (Fig. 5A). In addition, dual-luciferase reporter assay results demonstrated that the relative luciferase activities of TT and SW579 cell lines were significantly lower in the CCND1-WT + mimic groups compared with those of CCND1-WT + blank groups (P<0.01; Fig. 5B and C).

Downregulation of ZFAS1 expression levels reverses the promotive effects of miR-302a-3p inhibitor on CCND1 expression in thyroid carcinoma cells. Whether CCND1 expression was regulated by ZFAS1 and miR-302a-3p inhibitor in TT and SW579 cells was explored. The results demonstrated that CCND1 expression levels were significantly increased in TT and SW579 cells in the inhibitor group compared with those of the inhibitor-NC group (P<0.01; Fig. 6). In addition, CCND1 expression levels in the inhibitor + si-ZFAS1 group were significantly reduced compared with those of the inhibitor group, but were significantly increased compared with those in the si-ZFAS1 group (P<0.01; Fig. 6). These results suggested that the expression levels of miR-302a-3p and CCND1 were negatively associated, but that the expression levels of ZFAS1 and CCND1 were positively associated.

Downregulation of ZFAS1 expression levels eliminates the positive effects of miR-302a-3p inhibition on EMT of thyroid...
The expression levels of MMP2, MMP9, E-cadherin and N-cadherin were measured to detect the EMT of TT and SW579 cells with or without silencing the expression levels of miR-302a-3p and ZFAS1. The results demonstrated that the expression levels of MMP2, MMP9 and N-cadherin were significantly increased in the inhibitor group compared with those of the inhibitor-NC group (P<0.01; Fig. 7). In addition, the expression levels of MMP2, MMP9 and N-cadherin were significantly decreased in the inhibitor + si-ZFAS1 group compared with the inhibitor group, but were significantly increased compared with in the si-ZFAS1 group (P<0.01; Fig. 7). However, the changes in the expression levels of E-cadherin were the opposite to those observed MMP2, MMP9 and N-cadherin (P<0.01; Fig. 7). Thus, the results indicated that EMT was affected by miR-302a-3p and was regulated by ZFAS1.

Discussion

The present study revealed that ZFAS1 expression was increased in thyroid carcinoma tissues and cell lines, and that downregulation of ZFAS1 expression decreased the proliferation, migration, invasion and EMT of the tumor cells. These properties, however, were promoted by the inhibition
of miR-302a-3p expression, potentially by effects on CCND1 expression. These novel findings of a possible regulatory pathway may contribute to the development of interventions for thyroid carcinoma.

The results of the present study demonstrated that ZFAS1 expression levels were increased in thyroid carcinoma tissues and cell lines, and the proliferation, migration and invasion of TT and SW579 cells were reduced after silencing ZFAS1 expression levels. Dong et al. (32) reported that ZFAS1 overexpression facilitates the development of clear cell renal cell carcinoma. Additionally, Xie et al. (33) demonstrated that ZFAS1 promotes the metastasis of colorectal cancer by sponging miR-484. Thus, ZFAS1 is potentially a regulator in the progression of thyroid carcinoma.

The MMPs are a family of endogenous proteolytic enzymes with cofactors as metal ions (34). Hydrolyzed proteins require Zn$^{2+}$ and Ca$^{2+}$ to fulfill their functions (34). During the hydrolysis process, the MMP family serves an important role in hydrolyzing most of the extracellular matrix (ECM) components (35). The degradation of ECMs by MMPs affects a number of pathologically related physiological processes, such as the development of cancer, arthritis, genetic diseases, chronic renal failure and cardiovascular diseases (36,37). In cancer-related studies, abnormally expressed MMPs mainly affect tumor cell invasion and migration (37-39). MMP2 and MMP9 are two major members in MMPs and are widely used as the biomarkers of EMT in cancer research (40). EMT refers to the process

Figure 3. Negative correlation between the expression levels of ZFAS1 and miR-302a-3p. (A) Complementary sequences of ZFAS1 and miR-302a-3p. Relative luciferase activity in (B) TT and (C) SW579 cells treated with miR-302a-3p mimic. **P<0.01 vs. Blank. (D) miR-302a-3p expression levels in adjacent or cancer tissue. **P<0.01. (E) Correlation between miR-302a-3p and ZFAS1 expression. Relative miR-302a-3p expression levels in Control, inhibitor-NC, inhibitor, inhibitor + si-ZFAS1 and si-ZFAS1 groups in (F) TT and (G) SW579 cells. **P<0.01 vs. inhibitor-NC; **P<0.01 vs. inhibitor; ^^P<0.01 vs. inhibitor + si-ZFAS1. NC, negative control; si, small interfering; WT, wild-type; MUT, mutant; miR, microRNA.
during which epithelial cells change their protein expression levels and transform into mesenchymal cells under the effects of external factors (41). The cadherin family, a class of Ca\(^{2+}\)-dependent transmembrane glycoproteins, serves an important role in tissue morphogenesis and coordination of cell movement (42). E-cadherin and N-cadherin are two representatives of the cadherin family and are associated with EMT (43,44). Thus, increases in MMP2, MMP9, N-cadherin
expression levels, and decreased E-cadherin expression are indicative of EMT process.

The results of the present study indicated that miR-302a-3p expression was downregulated in thyroid carcinoma tissue and targeted by ZFAS1. In addition, inhibition of miR-302a-3p expression increased the proliferation, migration, invasion and EMT of thyroid carcinoma cells, and such effects were partially reversed by silencing ZFAS1. Zhang et al (45) demonstrated that inhibiting miR-302a-3p expression targets the suppressor of the cytokine signalling 5/STAT3 signaling axis and further promotes the metastasis of pancreatic cancer. Additionally, Pan et al (25) reported that miR-302a-3p overexpression is involved in the regulation of endometrial cancer, and it inhibits growth of endometrial cancer cells and is sponged by LINC01016. In addition, Ye et al (23) observed that the upregulation of miR-302a-3p suppresses the metastatic potential of hepatocellular carcinoma. Thus, miR-302a-3p expression serves a protective role in thyroid carcinoma. Taken together, it is hypothesized that the loss of miR-302a-3p expression contributes to the promotion of thyroid carcinoma, and this may be partially reversed by the downregulation of ZFAS1 expression.

The cyclin family are a class of proteins widely existing in eukaryotic cells (46); they function periodically in the cell cycle and act on cyclin-dependent kinases (CDKs) to regulate...
cell cycle progression (46). Among them, CCND1 is a highly conserved cell cycle family protein (47). CCND1 binds to CDKs, such as CDK4 or CDK6, to form complexes and act as their regulatory subunit, promoting cell cycle progression from G1 to S phase and completing the regulation of cell cycle (47). The overexpression of CCND1 occurs in different tumors, such as in breast cancer and gastric cancer, and promotes cell invasion and migration, leading to poor prognosis (48-50).

Guo et al (51) observed that the IncRNA NR2F1-AS1 sponged miRNA-338-3p to upregulate CCND1 expression and promote thyroid carcinoma progression. In addition, Jeon et al (52) proposed that the CCND1 splice variant may serve as a biomarker for the diagnostic and prediction of thyroid carcinoma. These findings confirmed that the overexpression of CCND1 serves a key role in the promotion of thyroid carcinoma. The results of the present study demonstrated that
Recent trends in the downregulation of ZFAS1 targeted and increased the expression of miR-302a-3p, which further suppressed the expression of CCND1, resulting in the inhibition of the proliferation, migration, invasion and EMT of thyroid carcinoma. These findings contribute to the development of drug for the treatment of thyroid carcinoma, however, the specific regulatory network should be further specified.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
WC designed and conceived the study, and wrote the manuscript. LZ, HL, YL, QZ, DX and WF acquired, analyzed and interpreted the data. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the ethics board of The First Hospital of Qiqihar (approval no. QR20180503112). Written informed consent was obtained from patients in the present study.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Liebner DA and Shah MH: Thyroid cancer: Pathogenesis and targeted therapy. Ther Adv Endocrinol Metab 2: 173-195, 2011.
2. Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol 2013: 965212, 2013.
3. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69: 7-34, 2019.
4. Ahn HS, Kim HJ and Welch HG: Korea’s thyroid-cancer ‘Epidemic’-screening and overdiagnosis. N Engl J Med 371: 1765-1767, 2014.
5. Colonna M, Uhry Z, Guizard AV, Delafosse P, Schwartz C, Belot A and Grosclaude P: FRANCIM network: Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol 39: 511-518, 2015.
6. Rhee YH, Moon JH, Choi SH and Ahn JC: Localuronium therapy promotes aggressive proliferation and angiogenesis through decreasing of transforming growth factor-β1 and increasing of Akt/Hypoxia inducible factor-1α in anaplastic thyroid cancer. Photomed Laser Surg 34: 229-235, 2016.
7. Calleender GG, Carling T, Christison-Lagay E and Udelman R: Surgery for thyroid cancer. Curr Opin Endocrinol Diabetes Obess 43: 443-458, 2014.
8. Sipos J and Mazzaferreri E: Thyroid cancer epidemiology and prognostic variables. Clin Oncol 22: 395-404, 2010.
9. Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell 136: 629-641, 2009.
10. Zhang Y and Tang L: The application of lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer Drug Discov 13: 292-301, 2018.
11. Ignarski M, Islam R and Müller RU: Long non-coding RNAs in kidney disease. Int J Mol Sci 20: 3276, 2019.
12. Xu YZ, Chen FF, Zhang Y, Zhao QF, Guan XL, Wang HY, Li A, Lv X, Song SS, Zhou Y and Li XJ: The long noncoding RNA FOXCUT promotes proliferation and migration by targeting FOXC1 in nasopharyngeal carcinoma. Tumour Biol 39: 1010428371706054, 2017.
13. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosony N, Barrette TR, Premsner JR, Evans JR, Zhao S, et al: The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 47: 199-208, 2015.
14. Li HJ, Li X, Pang H, Pan JX, Xie XJ and Chen W: Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer. Jpn J Clin Oncol 45: 1055-1063, 2015.
15. Tang X, Yin R, Shi H, Wang X, Shen D, Wang D and Pan C: lncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis. Int J Cardiol 315: 72-80, 2020.
16. Zhou HL, Zhou YF and Feng ZT: Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. Eur Rev Med Pharmacol Sci 23: 9840-9847, 2019.
17. Zhang J, Quan LN, Meng Q, Wang HY, Wang J, Yu P, Fu JT, Li YJ, Chen J, Chen H, et al: miR-545e sponged by ZFAS1 regulates metastasis and cisplatin resistance of OC by targeting CXCR4 and let-7a/BCL-XL/S signaling axis. Mol Ther Nucleic Acids 20: 621-638, 2020.
18. Zhang S, Wang J, Yao T and Tao M: lncRNA ZFAS1/miR-589 regulates the PTEN/PI3K/AKT signal pathway in the proliferation, invasion and migration of breast cancer cells. Cytotechnology 72: 415-425, 2020.
19. Pan J, Xu X and Wang G: lncRNA ZFAS1 is involved in the proliferation, invasion and metastasis of prostate cancer cells through competitively binding to miR-135a-5p. Cancer Manage Res 12: 1135-1149, 2020.
20. Han CG, Huang Y and Qin L: Long non-coding RNA ZFAS1 as a novel potential biomarker for predicting the prognosis of thyroid cancer. Med Sci Monit 25: 2984-2992, 2019.
21. Tong H, Zhang X, Cai J, Ding Y, Si Y, Zhang H and Shen M: Long noncoding RNA ZFAS1 promotes progression of papillary thyroid carcinoma by sponging miR-590-3p and upregulating HMGA2 expression. Onco Targets Ther 12: 7501-7512, 2019.
22. Yam C, Wong JH, Tsai SKW, Zuo T, Chan TF and Ng TB: lncRNAs with miRNAs in regulation of gastric, liver, colorectal cancers: Updates in recent years. App Microbiol Biotechnol 103: 4649-4677, 2019.
23. Ye Y, Song Y, Zhuang J, Wang G, Ni J, Zhang S and Xia W: MicroRNA-302a-3p suppresses hepatocellular carcinoma progression by inhibiting proliferation and invasion. Onco Targets Ther 11: 8175-8184, 2018.

24. Luo Z, Yi ZJ, Ou ZL, Han T, Wan T, Tang YC, Wang ZC and Huang FZ: RELA/NEAT1/miR-302a-3p/RELA feedback loop modulates pancreatic ductal adenocarcinoma cell proliferation and migration. J Cell Physiol 234: 3583-3597, 2019.

25. Pan X, Li D, Huo J, Kong F, Yang H and Ma X: LINC01016 promotes the malignant phenotype of endometrial cancer cells by regulating the miR-302a-3p/miR-3130-3p/NFYA/SATB1 axis. Cell Death Dis 9: 303, 2018.

26. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lottan R, Carey TE, et al: Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 17: 7248-7264, 2011.

27. Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY and Clayman GL: Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab 100: E243-E252, 2015.

28. Dutil J, Chen Z, Monteiro AN, Teer JK and Eschrich SA: An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res 79: 1263-1273, 2019.

29. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM and Paulin C: Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 73: 2206-2212, 1994.

30. Schewpe RE, Klopper JP, Korch C, Pugazhenthii U, Benezra M, Knauf JA, Fagin JA, Marzlow LA, Copland JA, Smallridge RC and Haugen BR: Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93: 4331-4341, 2008.

31. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

32. Dong D, Mu Z, Wei N, Sun M, Wang W, Xin N, Shao Y and Zhao C: Long non-coding RNA ZFAS1 promotes proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-10a/SKA1 pathway. Biomed Pharmacother 111: 917-925, 2019.

33. Xie S, Ge Q, Wang X, Sun X and Kang Y: Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer. Cell Cycle 17: 154-161, 2018.

34. Kapoor C, Vaidya S, Wadhwan V, Kaur G and Pathak A: Seesaw in invasion in colorectal cancer. Cell Cycle 17: 154‑161, 2018.

35. Xie S, Ge Q, Wang X, Sun X and Kang Y: Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer. Cell Cycle 17: 154-161, 2018.

36. Li F, Jin D, Guan L, Zhang CC, Wu T, Wang YJ and Gao DS: CEP55 promoted the migration, invasion and neurosphere formation of the glioma cell line U251. Neurosci Lett 705: 80-86, 2019.

37. Cheng D, Jiang S, Chen J, Li J, Ao L and Zhang Y: The increased IncRNA MIR503HG in preeclampsia modulated trophoblast cell proliferation, invasion, and migration via regulating matrix metalloproteinases and NF-xB signaling. Dis Markers 2019: 4976845, 2019.

38. Wang X, Yang B, She Y and Ye Y: The IncRNA TP73‑AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem 119: 7790-7799, 2018.

39. Yang J and Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 14: 818-829, 2008.

40. Fristam O, Ilieva I, Bock G and Veldman T: Long non-coding RNA NR2F1‑AS1 promotes ovarian cancer cell proliferation and metastasis. Oncotarget 10: 20161-20172, 2019.

41. Abdallah RA, Abdou AG, Abdelwahed M and Ali H: Immunohistochemical expression of E- and N-Cadherin in nodular prostatic hyperplasia and prostatic carcinoma. J Microse Ultrastruct 7: 19-27, 2019.

42. Oyste KAB, Berg JP, Normann KR, Zucknick M, Casar-Borota O and Bollerslev J: The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours. Endocrine 62: 351-360, 2018.

43. Zhang Z, Li J, Guo H, Wang F, Ma L, Du C, Wang Y, Wang Q, Kornmann M, Tian X and Yang Y: BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis. Cancer Lett 449: 215-225, 2019.

44. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9: 153-166, 2009.

45. Li X, Huo X, Li W, Yang Q, Wang Y and Kang X: Genetic association between cyclin D1 polymorphism and breast cancer susceptibility. Tumour Biol 35: 11959-11965, 2014.

46. Neumeister P, Pixley FJ, Xiong Y, Xie H, Wu K, Ashton A, Cammer M, Chan A, Symons M, Stanley ER and Pestell RG: Cyclin D1 governs adhesion and motility of macrophages. Mol Biol Cell 14: 2005-2015, 2003.

47. Zheng Z, Yeow WS, Zou C, Wassell R, Wang C, Pestell RG, Quong JN and Quong AA: Cyclin D1/cyclin-dependent kinase 4 interacts with filament A and affects the migration and invasion potential of breast cancer cells. Cancer Res 70: 2105-2114, 2010.

48. Ullah Shah A, Mahjabeen I and Kayani MA: Genetic polymorphisms in cell cycle regulatory genes CCND1 and CDK4 are associated with susceptibility to breast cancer. J BUON 20: 985-993, 2015.

49. Guo F, Fu Q, Wang Y and Sui G: Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis. J Cell Mol Med 23: 5907-5919, 2019.

50. Jeon S, Kim Y, Jeong YM, Baes JH and Jung CK: CCND1 splice variant as a novel diagnostic and predictive biomarker for thyroid cancer. Cancers (Basel) 10: 437, 2018.